Price: $36.6100
$2.04
5.901%
|
Day's High:
| $36.8
| Week Perf:
| -2.79 %
|
Day's Low: |
$ 34.40 |
30 Day Perf: |
-30.5 % |
Volume (M): |
1,753 |
52 Wk High: |
$ 109.52 |
Volume (M$): |
$ 64,192 |
52 Wk Avg: |
$76.48 |
Open: |
$34.50 |
52 Wk Low: |
$34.09 |
|
|
Market Capitalization (Millions $) |
400 |
Shares
Outstanding (Millions) |
11 |
Employees |
425 |
Revenues (TTM) (Millions $) |
1,072 |
Net Income (TTM) (Millions $) |
99 |
Cash Flow (TTM) (Millions $) |
7 |
Capital Exp. (TTM) (Millions $) |
6 |
Medifast Inc
Medifast, Inc. is engaged in the production, distribution, and sale of weight
loss, weight management, and healthy living products and other consumable health
and diet products. The Company primarily operates through its wholly owned subsidiaries,
Jason Pharmaceuticals, Inc., Take Shape For Life, LLC, Jason Enterprises, Inc.,
Medifast Franchise Systems (“MFSI”), Inc., Jason Properties, LLC,
Medifast Nutrition, Inc. and Seven Crondall, LLC. Medifast product lines include
weight loss, weight management, and healthy living meal replacements, snacks,
hydration products and vitamins. The Company manufactures a significant portion
of its products at its manufacturing facility located in Owings Mills, Maryland.
Over the past 30 years, obesity in the United States has risen dramatically.
In 2013, the American Medical Association officially declared obesity a disease
and The American Heart Association, the American College of Cardiology, and
The Obesity Society recommended that obesity be managed as a chronic disease.
Throughout the world, the World Health Organization estimates that approximately
1.9 billion people are overweight. In the United States, over two-thirds of
the adult population fall within the overweight or obese categories. According
to the Centers for Disease Control and Prevention (“CDC”), over
78 million U.S. adults are obese.
Furthermore, the CDC reported that forty-five states had adult obesity rates
of 25% or higher, and twenty-two of these states had obesity rates at 30% or
more. Being overweight and/or obese is linked to a multitude of serious comorbidities
including heart disease, stroke, Type 2 diabetes, certain types of cancers,
arthritis, sleep apnea and depression.
The primary factors contributing to obesity, which are well known are: unhealthy
food choices and lack of physical activity. Obesity is not limited to adults;
the CDC has reported children and adolescents are also affected. According to
the CDC, the prevalence of obesity in children age 6-11 years has doubled and
obesity rates have quadrupled in adolescents age 12-19 years in the past 30
years.
The U.S. weight loss market itself is estimated to be a $65 billion per year
industry, including consumer spending on diet foods, drinks and low-calorie
sweeteners; health clubs and workout videos; medically supervised and commercial
weight loss programs; children’s weight loss camps; diet books; appetite
suppressants and more. Portion-controlled, meal-replacement weight management
programs are continuing to gain popularity, as consumers search for a safe and
effective solution that provides balanced nutrition, effective weight loss,
and valuable behavior-modification education.
Company Address: 100 International Drive Baltimore 21202 MD
Company Phone Number: 581-8042 Stock Exchange / Ticker: NYSE MED
|
|
Customers Net Income fell by |
MED's Customers Net Profit Margin fell to |
-45.88 % |
3.34 %
|
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Medifast Inc
Medifast Inc, a renowned health and wellness company known for its lifestyle solution OPTAVIA, recently reported its financial results for the fourth quarter and full year of 2023. While the company has embarked on a transformative business phase, expanding its reach in the health and wellness market, it is facing tough competition and experiencing significant declines in revenue and profitability. Financial Performance: In the fourth quarter of 2023, Medifast's net profit per share plummeted by a staggering -77.21%, dropping to $0.55 per share compared to $2.43 per share in the previous year. Earnings per share also fell by -73.86% to $2.12 per share. The company's revenue declined by -43.135% to $191.78 million compared to $337.25 million in the same period the previous year.
|
Business Update
Published Wed, Dec 13 2023 11:00 AM UTC
Medifast, the renowned health and wellness company recognized for its habit-based and coach-guided lifestyle solution, OPTAVIA, has commenced the transformative first phase of its business transformation, with a determined focus on expanding its reach to offer comprehensive health and wellness solutions across the United States. The Baltimore-based company is makin...
|
Medifast Inc
Medifast Inc., the renowned health and wellness company, recently released its financial results for the third quarter ending September 30, 2023. The figures paint a mixed picture, as certain key metrics suffered significant declines, while others showed signs of improvement. In this article, we'll delve into the company's financial performance and assess its potential impact on Medifast's future. Earnings and Income: Medifast Inc.'s earnings per share (EPS) experienced a substantial drop of -35.17% in the July to September 30, 2023 interval, falling from $3.27 per share to $2.12 per share compared to the previous year. Additionally, net income decreased by -23.47% from $2.77 per share in the prior reporting period. These declines in earnings and income raise concerns about the company's ability to maintain profitability.
|
Medifast Inc
Medifast Inc, a leading health and wellness company, recently released its financial results for the most recent fiscal period. This article aims to provide an overview and analysis of these results, highlighting key figures and trends that may impact the company's performance and prospects for the future. Financial Results Overview: 1. Income: - In the most recent fiscal period, Medifast Inc witnessed a decline in income of -19.01% to $2.77 per share, compared to $3.42 per share in the previous year. - Income also faded by -24.52% from $3.67 per share in the prior financial reporting period.
|
Medifast Inc
Investing in the stock market can be a daunting task, especially in times of economic uncertainty. While the recent news about Medifast Inc's return on equity (ROE) might seem promising, caution is still necessary when making investment decisions. It is important to note that while Medifast Inc achieved a new company high ROE of 93.58% in the first quarter of 2023, this was largely due to net income growth. The company also achieved the highest return on equity within the Nonalcoholic Beverages industry; however, its overall ranking has only advanced to 10 from the previous quarter's ranking of 94.
|
Per Share |
Current |
Earnings (TTM) |
9.11 $ |
Revenues (TTM) |
98.11 $
|
Cash Flow (TTM) |
0.62 $ |
Cash |
8.64 $
|
Book Value |
18.44 $
|
Dividend (TTM) |
4.95 $ |
|
Per Share |
|
Earnings (TTM) |
9.11 $
|
Revenues (TTM) |
98.11 $ |
Cash Flow (TTM) |
0.62 $ |
Cash |
8.64 $
|
Book Value |
18.44 $ |
Dividend (TTM) |
4.95 $ |
|
|
|
|